Arthur P. Bertolino

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

Wolfgang Hueber, Bruce E. Sands, Steve Lewitzky et al. · Gut · 2012 · 1.5K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +15

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Dominique Baeten, Xenofon Baraliakos, Jürgen Braun et al. · The Lancet · 2013 · 590 citations

Medicine, Clinical Sciences, Immunology +14

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Iain B. McInnes, Joachim Sieper, Jürgen Braun et al. · Annals of the Rheumatic Diseases · 2013 · 341 citations

Medicine, Immunology, Pharmacotherapy +15

Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor

Hans Skvara, Frank Kalthoff, Josef G. Meingassner et al. · Journal of Investigative Dermatology · 2011 · 148 citations · Full text

Medicine, Dermatology, Oncology +11

Differential Expression of Type I Hair Keratins

Arthur P. Bertolino, Daniel M. Checkla, Sheila Heitner et al. · Journal of Investigative Dermatology · 1990 · 51 citations

Life Sciences, Dermatology, Molecular Biology +9